[go: up one dir, main page]

PE2499A1 - COATING COMPOSITIONS THAT CONTROL RELEASE - Google Patents

COATING COMPOSITIONS THAT CONTROL RELEASE

Info

Publication number
PE2499A1
PE2499A1 PE1997000805A PE00080597A PE2499A1 PE 2499 A1 PE2499 A1 PE 2499A1 PE 1997000805 A PE1997000805 A PE 1997000805A PE 00080597 A PE00080597 A PE 00080597A PE 2499 A1 PE2499 A1 PE 2499A1
Authority
PE
Peru
Prior art keywords
active substance
dihydrogenocitrate
matrix
sodium
subject
Prior art date
Application number
PE1997000805A
Other languages
Spanish (es)
Inventor
James Albert Napper
Susan Marie Milosovich
William Muldoon
Laurence Rousseau
Joseph Sauer
Original Assignee
Smithkline Beecham Plc
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc, Smithkline Beecham Corp filed Critical Smithkline Beecham Plc
Publication of PE2499A1 publication Critical patent/PE2499A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

CARACTERIZADAS PORQUE COMPRENDEN COMO PRINCIPIO ACTIVO EL MONOHIDROCLORURO DE [R-(Z)]-O-(METOXIIMINO)-O-(1-AZABICICLO[2.2.2]OCT-3-IL) ACETONITRILO; Y TRATANDOSE DE (1) UN COMPRIMIDO QUE INCLUYE UNA MATRIZ, QUE COMPRENDE: DE 0,005 mg A 0,1 mg DEL PRINCIPIO ACTIVO; 75 mg DE HIDROXIPROPILMETILCELULOSA E4M CR; 3 mg DE DIHIDROGENOCITRATO DE SODIO; 70,38 mg DE LACTOSA, FAST FLO; 1,5 mg DE ESTEARATO DE MAGNESIO; 2,25 mg DE OPADRY WHITE; Y (2) GRANULOS O ESFERAS PARA PREPARAR CAPSULAS, QUE COMPRENDE: DE 0,003% P/P A 0,06% P/P (CALCULADO COMO BASE LIBRE) DEL PRINCIPIO ACTIVO; 3% P/P DE OPADRY CLEAR; 1,5% P/P DE DIHIDROGENOCITRATO DE SODIO; AMBAS COMPOSICIONES SE SOMETEN A RECUBRIMIENTOS: PRIMERO DE SELLADO, QUE CONSISTE EN OPADRY CLEAR (YS-1-9025A) AL 10 % DE SOLIDOS, EN AGUA; SEGUNDO, RECUBRIMIENTO POLIMERICO, QUE CONSISTE DE ETILCELULOSA (SURELEASE) AL 25 % DE SOLIDOS, EN AGUA; Y FINALMENTE UN TERCER RECUBRIMIENTO DE SELLADO; LA COMPOSICION QUE INCLUYE MATRIZ, SE SOMETE A UN CUARTO RECUBRIMIENTO POLIMERICO. ESTAS COMPOSICIONES LIBERAN EL PRINCIPIO ACTIVO EN EL TRACTO DIGESTIVO DURANTE 8 A 12 HORAS DESPUES DE LA INGESTION; DICHO PRINCIPIO ACTIVO ACTUA MEJORANDO EL PROCESADO DE LA PROTEINA PRECURSORA AMILOIDE POR UNA VIA AMILOIDOGENICA, SIENDO UTIL EN LA PREVENCION Y TRATAMIENTO DE LA DEMENCIA Y LA ENFERMEDAD DE ALZHEIMERCHARACTERIZED BECAUSE THEY INCLUDE AS ACTIVE SUBSTANCE THE MONOHIDROCHLORIDE OF [R- (Z)] - O- (METOXIIMINO) -O- (1-AZABICICLO [2.2.2] OCT-3-IL) ACETONITRILE; AND IN THE CASE OF (1) A TABLET INCLUDING A MATRIX, INCLUDING: 0.005 mg TO 0.1 mg OF THE ACTIVE SUBSTANCE; HIDROXIPROPILMETILCELULOSA E4M CR 75 mg; 3 mg SODIUM DIHYDROGENOCITRATE; 70.38 mg LACTOSE, FAST FLO; 1.5 mg MAGNESIUM STEARATE; 2.25 mg OPADRY WHITE; AND (2) GRANULES OR SPHERES TO PREPARE CAPSULES, WHICH INCLUDES: FROM 0.003% P / P TO 0.06% P / P (CALCULATED AS A FREE BASE) OF THE ACTIVE SUBSTANCE; 3% P / P OF OPADRY CLEAR; 1.5% W / W OF SODIUM DIHYDROGENOCITRATE; BOTH COMPOSITIONS ARE SUBJECT TO COATINGS: FIRST SEALING, WHICH CONSISTS OF 10% SOLID OPADRY CLEAR (YS-1-9025A), IN WATER; SECOND, POLYMERIC COATING, WHICH CONSISTS OF 25% SOLID ETHYL CELLULOSE (SURELEASE), IN WATER; AND FINALLY A THIRD SEAL COATING; THE COMPOSITION INCLUDING A MATRIX IS SUBJECT TO A FOURTH POLYMER COATING. THESE COMPOSITIONS RELEASE THE ACTIVE SUBSTANCE IN THE DIGESTIVE TRACT DURING 8 TO 12 HOURS AFTER INGESTION; SUCH ACTIVE PRINCIPLE WORKS IMPROVING THE PROCESSING OF AMYLOID PRECURSORY PROTEIN THROUGH AN AMYLOIDOGENIC VIA, BEING USEFUL IN THE PREVENTION AND TREATMENT OF ALZHEIMER'S DEMENTIA AND DISEASE

PE1997000805A 1996-09-12 1997-09-10 COATING COMPOSITIONS THAT CONTROL RELEASE PE2499A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9619074.9A GB9619074D0 (en) 1996-09-12 1996-09-12 Composition

Publications (1)

Publication Number Publication Date
PE2499A1 true PE2499A1 (en) 1999-03-24

Family

ID=10799833

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1997000805A PE2499A1 (en) 1996-09-12 1997-09-10 COATING COMPOSITIONS THAT CONTROL RELEASE

Country Status (22)

Country Link
EP (1) EP0929301A2 (en)
JP (1) JP2001500150A (en)
KR (1) KR20000036039A (en)
CN (2) CN1235544A (en)
AR (1) AR008176A1 (en)
AU (1) AU724086B2 (en)
BR (1) BR9711734A (en)
CA (1) CA2265661A1 (en)
CO (1) CO5031291A1 (en)
CZ (1) CZ83299A3 (en)
GB (1) GB9619074D0 (en)
HU (1) HUP9904401A3 (en)
ID (1) ID19589A (en)
IL (1) IL128781A0 (en)
MA (1) MA24359A1 (en)
NO (1) NO991194L (en)
NZ (1) NZ334268A (en)
PE (1) PE2499A1 (en)
PL (1) PL332074A1 (en)
TR (1) TR199900505T2 (en)
WO (1) WO1998010762A2 (en)
ZA (1) ZA978133B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2775597B1 (en) * 1998-03-04 2001-04-20 Gattefosse Ets Sa ORAL PELLET ADAPTED TO IMPROVE THE BIOAVAILABILITY OF THE ACTIVE SUBSTANCE, METHOD OF MANUFACTURE
CA2323177A1 (en) 1998-03-11 1999-09-16 Susan Marie Milosovich Composition
DE19918325A1 (en) * 1999-04-22 2000-10-26 Euro Celtique Sa Extruded drug dosage form, e.g. granulate for tableting, comprising an active agent in a polysaccharide-containing matrix, giving a release profile which is controllable by extrusion conditions and/or the inclusion of additives
FR2796840B1 (en) 1999-07-26 2003-06-20 Ethypharm Lab Prod Ethiques LOW-DOSE TABLETS AND METHOD OF PREPARATION
US6733781B2 (en) 2000-12-06 2004-05-11 Wyeth Fast dissolving tablet
MY142204A (en) 2002-07-25 2010-10-29 Pharmacia Corp Pramipexole once-daily dosage form
CA2520813C (en) * 2003-04-25 2009-10-27 Mitsubishi Pharma Corporation Sustained release formulations of alkylene dioxybenzene derivatives useful as 5-ht1a agonists
ATE339192T1 (en) * 2003-05-14 2006-10-15 Eurand Pharmaceuticals Ltd CONTROLLED DRUG RELEASE COMPOSITION WITH IN VIVO MECHANICAL STRESS RESISTANCE
US20050142191A1 (en) * 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
JP2005272347A (en) * 2004-03-24 2005-10-06 Ohara Yakuhin Kogyo Kk Method for producing solid preparation
KR20070050081A (en) 2004-08-13 2007-05-14 베링거 인겔하임 인터내셔날 게엠베하 Extended release pellet formulation comprising pramipexole or a pharmaceutically acceptable salt thereof, preparation method thereof and use thereof
BRPI0513847A (en) 2004-08-13 2008-05-20 Boehringer Ingelheim Int extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method of manufacture thereof and use thereof
EP1970056A1 (en) * 2007-03-15 2008-09-17 Polichem S.A. Time-specific delayed/pulsatile release dosage forms
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0392803T3 (en) * 1989-04-13 2004-10-18 Beecham Group Plc Hitherto unknown compounds
GB9409718D0 (en) * 1994-05-14 1994-07-06 Smithkline Beecham Plc Novel compounds
GB9421472D0 (en) * 1994-10-25 1994-12-07 Smithkline Beecham Plc Novel methods
AR004178A1 (en) * 1995-07-29 1998-11-04 Smithkline Beecham Plc PROCEDURE FOR THE FORMULATION OF A PHARMACY, A PHARMACEUTICAL COMPOSITION OBTAINABLE THROUGH THIS PROCEDURE AND THE USE OF THE SAME.

Also Published As

Publication number Publication date
WO1998010762A3 (en) 1998-06-04
CZ83299A3 (en) 1999-08-11
MA24359A1 (en) 1998-07-01
KR20000036039A (en) 2000-06-26
WO1998010762A2 (en) 1998-03-19
ID19589A (en) 1998-07-23
CN1235544A (en) 1999-11-17
NO991194D0 (en) 1999-03-11
CN1446535A (en) 2003-10-08
JP2001500150A (en) 2001-01-09
AU4128897A (en) 1998-04-02
HUP9904401A3 (en) 2001-03-28
PL332074A1 (en) 1999-08-30
CO5031291A1 (en) 2001-04-27
AU724086B2 (en) 2000-09-14
EP0929301A2 (en) 1999-07-21
NO991194L (en) 1999-03-11
AR008176A1 (en) 1999-12-09
HUP9904401A2 (en) 2000-06-28
IL128781A0 (en) 2000-01-31
CA2265661A1 (en) 1998-03-19
NZ334268A (en) 2000-10-27
TR199900505T2 (en) 1999-06-21
GB9619074D0 (en) 1996-10-23
ZA978133B (en) 1999-04-12
BR9711734A (en) 1999-08-24

Similar Documents

Publication Publication Date Title
PE2499A1 (en) COATING COMPOSITIONS THAT CONTROL RELEASE
US6177102B1 (en) Once daily analgesic tablet
US6531152B1 (en) Immediate release gastrointestinal drug delivery system
EP1021171B1 (en) Delayed total release gastrointestinal drug delivery system
US5750145A (en) Stable gelatin coated aspirin tablets
Bernkop-Schnurch et al. Multifunctional matrices for oral peptide delivery
AU674583B2 (en) Stable, ingestable and absorbable NADH and NADPH therapeutic compositions
FI88675C (en) Elastic film retraction and derivation
CA2170748A1 (en) Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis
ES2245071T3 (en) PROCEDURE TO OBTAIN A PREPARATION OF DELAYED TRAMADOL WITH A STABLE RELEASE PROFILE IN STORAGE WITHOUT NEED TO TREAT THE COATED PRODUCT THERMALLY.
IL118240A (en) Oral coated capsule dosage form of omega-3 polyunsaturated acid for release of the acid in the intestine
BRPI0317682B1 (en) Modified release pharmaceutical composition in capsule form
UA72483C2 (en) Moxifloxacin-containing pharmaceutical preparation and method for its manufacture
HUP9900800A2 (en) Improvements in or relating to organic compositions
TW200602085A (en) Controlled-release pharmaceutical composition and method for producing same
CA2229283A1 (en) Prednisolone metasulphobenzoate preparation for the treatment of inflammatory bowel disease
CA2219777A1 (en) Nanoparticles for oral administration of pharmaceutical agents of low solubility
BR0212155A (en) Pharmaceutical Composition
HUP0001084A2 (en) Modified release oral pharmaceutical composition containing 5-asa for the treatment of bowel diseases
US5958873A (en) Oral formulation for treatment of bacteria-induced diseases of the colon
CA2055905A1 (en) Pharmaceutical composition comprising calcium polycarbophil
ES2234301T3 (en) ACETAMINOFENO DE PROLONGADA LIBERACION.
FR2845289B1 (en) SPHEROIDS, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS.
BR9912533A (en) Pharmaceutical composition having improved taste
RU97113855A (en) SOLID INSULIN-CONTAINING MEDICINE

Legal Events

Date Code Title Description
FD Application declared void or lapsed